Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

BRISBANE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the second quarter and six months ended June 30, 2009. InterMune reported a net loss for the second quarter of 2009 of $36.7 million, or $0.81 per share, compared with a net loss of $29.6 million, or $0.76 per share, in the second quarter of 2008.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "The last several months have been exceptionally productive for InterMune and the coming months promise to be even more so. Regarding pirfenidone, we have made excellent progress on the preparation of our New Drug Application (NDA) for pirfenidone which we now expect to submit in the fourth quarter. It has taken more time than we anticipated to integrate the advice of a host of external expert advisors and to take every possible step to develop the strongest possible file that positions us for potential approval in the first review cycle. Our Marketing Authorization Application (MAA) is also progressing very well; we had a successful pre-submission meeting with the EMEA in July and we expect to submit the MAA for pirfenidone in the first quarter of 2010."

Mr. Welch continued, "Regarding ITMN-191 (R7227), we announced exciting news today on several important aspects of the program, specifically: the successful completion of six-month and nine-month chronic toxicology studies in rats and monkeys, respectively which clear the way for our Phase 2 and Phase 3 clinical programs; our expectation that our partner Roche will enroll the first patient in our Phase 2b study of ITMN-191 in combination with standard of care in August; our plans to start a Phase 1b MAD study of ITMN-191 in combination with low dose ritonavir in HCV patients in the thi
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ovember 20 Karolinska Development ...nd (EIF) has entered into a,co-investment agreemen...,managed by Karolinska Development and used to inv...maceutical and medical technology companies. EIF,h...ent fund. The agreement,represents EIF,s largest s...
(Date:11/19/2009)...PRNewswire/ -- Danish Prince Joachim inaugurated t...t in Kalundborg, Denmark, on Wednesday, November 1...rgest 2nd generation ethanol demonstration biorefi... the plant,s innovative process for converting str...he first to market with commercial enzymes for con...
(Date:11/19/2009)...19 Spherix Incorporated ...r diabetes therapy, and a provider of technical an...nt, biotechnology and pharmaceutical companies, to...ing of Shareholders. ,, At the meeting, shareho...cted the following members to the Board of Directo...
(Date:11/19/2009)...,s Top Gene Synthesis Companies Form International...st Practices in Risk Reduction ,Five Member Comp...esis Capacity , (PRWEB) N...ing gene synthesis companies today announced agree...col to promote biosecurity in the gene synthesis i...
Breaking Biology Technology:Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
... SUNNYVALE, Calif., Jan. 14 Accuray Incorporated,... radiosurgery, today announced,that it will report...ending,December 27, 2008, on Thursday, January 29,...call to review the results will begin at 2:00 p.m.... Thomson, Ph.D., president and chief,executive off...
... LEOMINSTER, Mass., Jan. 14 PolyOrg, Inc. a Massa... non-exclusive license agreement with,the Copenhag...ure and,distribute PNA monomers worldwide. , "... license to sell PNA,monomers," said Peter Nielsen...n , Denmark and co-inventor of PNA. "Ready availab...
... Comprehensive tutorials on t...d UniProt databases enable researchers to quickly ... Seattle (PRWEB) January 1...ility of new tutorial suites on PROSITE, InterPro ...l on UniProt. PROSITE is a database that can be ...
Other Biology Technology:Accuray Incorporated to Report Second Quarter Fiscal Year 2009 Financial Results 2PolyOrg, Inc. Acquires a License to Manufacture and Distribute PNA Monomers Worldwide 2New and Updated Online Tutorials for PROSITE, InterPro, IntAct and UniProt 2New and Updated Online Tutorials for PROSITE, InterPro, IntAct and UniProt 3
(Date:11/23/2009)..., , , , , , , , , , ... , , AUDIO: , Dr Andrew Mar...ersity of York, discusses the discovery of Kinyon... , Click here for more information... , , , , , , , ...
(Date:11/23/2009)..., , Scientists have revealed how environmental i... cause people to cough, in research published toda...ical Care Medicine . The authors of the study, fro...ll, have identified the reaction inside the lungs ... to particular irritants in the air. They suggest ...
(Date:11/23/2009)..., This release is available in German . , ...ce a long journey every year. Researchers at Princ...Institute for Ornithology in Radolfzell, Germany s...nt family of bats, the so-called "Vespertilionidae...vered that the migration over short as well as lon...
Breaking Biology News(10 mins):New chameleon species discovered in East Africa 2New chameleon species discovered in East Africa 3Research reveals exactly how coughing is triggered by environmental irritants 2We're off then: The evolution of bat migration 2Carnegie Mellon customizing electric cars for cost effective urban commuting 10732 1Carnegie Mellon customizing electric cars for cost effective urban commuting 10732 2Carnegie Mellon customizing electric cars for cost effective urban commuting 10732 3NeoVista Inc Announces the Launch of VIDION ANV Therapy System in UK for Treating Wet Age Related Macular Degeneration 61416 1NeoVista Inc Announces the Launch of VIDION ANV Therapy System in UK for Treating Wet Age Related Macular Degeneration 61416 2NeoVista Inc Announces the Launch of VIDION ANV Therapy System in UK for Treating Wet Age Related Macular Degeneration 61416 3Hollis Eden Presents New Interim Data From Prostate Cancer Phase I II Clinical Studies of Apoptone 28HE3235 29 at AACR Molecular Targets and Cancer T 14849 1Hollis Eden Presents New Interim Data From Prostate Cancer Phase I II Clinical Studies of Apoptone 28HE3235 29 at AACR Molecular Targets and Cancer T 14849 2Hollis Eden Presents New Interim Data From Prostate Cancer Phase I II Clinical Studies of Apoptone 28HE3235 29 at AACR Molecular Targets and Cancer T 14849 3Hollis Eden Presents New Interim Data From Prostate Cancer Phase I II Clinical Studies of Apoptone 28HE3235 29 at AACR Molecular Targets and Cancer T 14849 4
...share of grants totalling over 1m to target lung i...n Bates, a senior lecturer in the Department of En...cipient of 1,068,000 in the form of just two resea...Sciences Research Council (EPSRC) and the other fr...rch Council (BBSRC). , The grants are shared betw...
...nterior to determine if global warming threatens t...ot be used to justify listing the polar bear as an...blished later this year in Interfaces, a journal o...nagement Sciences (INFORMS)., On April 30, U.S. Di...epartment to decide by May 15 whether polar bears ...
...ess struggle to stay primed, researchers in Spain ...t and business practice is needed if a company is ...f Management Practice from Inderscience Publishers...e from nature to them restructure. , Palmira Lpez...rnando Fernndez-Gonzlez of the Hospital Central de...
Other Biology News:Engineer to spearhead research into cell metabolism and medical injuries 2Federal polar bear research critically flawed, says study in INFORMS journal 2Programmed death boosts business 2
...ve, cost-effective solution to your TechMate Detec...ted quality into both our products and service cap...ies and antibodies that have been optimized to the...vely priced accessories that can be purchased indi...
...is buffer, PCR mix, DNA polymerase and universal c...This system can detect different types of Gram neg... Escherichia Coli, Klebsiella Pneumoniae, Bacillus...actiae, and etc. With the powerful Universal lysis...
pTRI-GAPDH-Human (316 bp protected fragment) from Ambion
...timized for serum-free growth of Ready-Plaque Sf9 ... Sf9 cultures routinely reach densities greater th...is medium is also recommended for plaque assays, w...nants develops faster than other formulations. Cel...
Biology Products: